Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress
Brief Summary: The purpose of this study is to assess the tolerability, safety, and efficacy of brexpiprazole (2.0 mg/day) as adjunctive therapy in adult subjects with a diagnosis of MDD with and without anxious distress


Options:
A: Inclusion Criteria:

* Male or female subjects between 18 and 65 years of age, with diagnosis of major depressive disorder, as defined by DSM-IV-TR criteria
* The current depressive episode must be equal to or greater than 8 weeks in duration
* Subjects must report a history for the current depressive episode of an inadequate response to no more than three adequate antidepressant treatments

Exclusion Criteria:

* Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug
* Subjects who report an inadequate response to more than three adequate trials of antidepressant treatments during current depressive episode at a therapeutic dose for an adequate duration
* Subjects with a current Axis I (DSM-IV-TR) diagnosis of: Delirium, dementia, amnestic or other cognitive disorder, Schizophrenia, schizoaffective disorder, or other psychotic disorder, Bipolar I or II disorder
* Subjects with a clinically significant current Axis II (DSM-IV-TR) diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorder
B: Inclusion Criteria:

1. 18 - 60 years
2. Major depression according to DSM-IV
3. Living within 30 km of training facilities
4. Able to read and understand informed consent

Exclusion Criteria:

1. Recreational or current drug abuse
2. Having used antidepressant medication within the last 2 months
3. Contraindications to physical exercise
4. Recreational exercise\> 1 hour per week
5. Medication for diabetes, hypertension, or any kidney disease
6. Suicidal behaviour (ham-d17 item3 \> 2)
C: Inclusion Criteria:

Veterans will be considered eligible for study participation if the following criteria are met:

* 18 years of age (no maximum age is specified)
* working for pay 15 hours per week
* employed in the job for 6 months (to ensure that the Veteran has sufficient familiarity with the position and organization)
* current major depression and/or persistent depressive disorder symptoms based on DSM-5 criteria
* and current work limitations

Exclusion Criteria:

* Non-English speaking or reading
* bipolar disorder
* psychosis
* and/or planning to take maternity leave at any point in the next nine months
D: Inclusion Criteria:

* Male and Female subjects between 18-65 years of age, with diagnosis of major depressive disorder with or without anxious distress
* Current depressive episode must be at least 8 weeks in duration

Exclusion Criteria:

* Subjects with a history of Neuroleptic Malignant Syndrome or Serotonin Syndrome
* Subjects who report an inadequate response to more than 3 antidepressant treatments in the current episode
* Subjects with a current Axis I diagnosis of: Delirium, dementia, amnestic or other cognitive disorder, Schizophrenia, schizoaffective disorder, or other psychotic disorder, Bipolar I or II disorder

Answer: D